Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug
June 27th 2017Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
Telemedicine: Reimbursement in fee-for-service, quality models
March 22nd 2017The provision of health care via technology and without direct eye-to-eye and skin-to-skin contact is an area of growing interest in the U.S. It is also an area of great concern. One of the key conundrums surrounding telemedicine is the when, how, and what to pay for the service.
Value-based pay in 2017: Where does urology fit?
March 22nd 2017Value-based payment models tend to fall into three general categories: shared savings programs, capitation models, and episode-of-care models. In this article, Robert A. Dowling, MD, reviews the current landscape of these payment models, including public and private-sector models that may serve as examples for urology.
OIG targets IMRT, chronic care payments in 2017
February 1st 2017Each year, the Office of the Inspector General at the Department of Health and Human Services publishes a summary of its activities and a work plan for the coming year. What follows is a summary of new topics in the FY2017 work plan that may be of interest to urologists.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agent
January 13th 2017Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.